EValuating the Effect of periopeRaTIve empaGliflOzin on cardiac surgery associated acute kidney injury: rationale and design of the VERTIGO study.

Armando Coca-RojoElena Bustamante-MunguiraVerónica FidalgoManuel FernándezCristina AbadMarta FrancoÁngel González-PintoDaniel PeredaSergio CánovasJuan Bustamante-Munguira

Published in: Clinical kidney journal (2024)

The VERTIGO trial will describe the efficacy and safety of empagliflozin in preventing CSA-AKI. Patient recruitment is expected to start in May 2024.

Keyphrases

acute kidney injury
cardiac surgery
clinical trial
study protocol
patients undergoing
phase ii